Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer

Basit Öğe Kaydı
dc.contributor.authorKaraca, Halit
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorDemirci, Umut
dc.contributor.authorAlıcı, Süleyman
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.date.accessioned2020-03-26T18:41:45Z
dc.date.available2020-03-26T18:41:45Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractErlotinib is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, with single-agent antitumor activity which improves symptom control and quality of life compared with placebo in non-small-cell-lung cancer (NSCLC) patients. We aimed to determine the efficacy and safety of the second, third or fourth-line erlotinib in advanced NSCLC patients in Turkish population. Eighty patients (33 males and 47 females) were retrospectively evaluated. All patients had received a platinum-based regimen as the first-line metastatic therapy. Most of the patients (62.5%) had received erlotinib as the second-line treatment. None of the patients had EGFR mutation studied. One patient achieved a complete response, 10 patients partial response and 21 stable diseases. The overall response rate was 14% and disease control rate was 40%. The median progression-free survival (PFS) and overall survival (OS) were 12 months and 18 months, respectively. Although, there was no survival difference between male and female patients, the median PFS of females was significantly better than male patients (p=0.03). There was no significant difference in disease control rate in terms of age, smoking status, erlotinib line, performance status (PS), stage and skin rash. The most common adverse events were skin rash (56%), diarrhea (9%) and anorexia (8%). Sixteen patients (20%) developed grade 3 toxicities. Grade 4 toxicity or treatment related interstitial lung disease were not observed. Erlotinib showed an acceptable response rate, survival time and toxicity after disease progression with chemotherapy. It's an alternative therapy as a second or third-line therapy in patients with NSCLC. Prospective studies are needed to evaluate the efficiency of the treatment in Turkish population.en_US
dc.identifier.doi10.4999/uhod.12009en_US
dc.identifier.endpage6en_US
dc.identifier.issn1306-133Xen_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://dx.doi.org/10.4999/uhod.12009
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29455
dc.identifier.volume23en_US
dc.identifier.wosWOS:000317021900001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherAKAD DOKTORLAR YAYINEVIen_US
dc.relation.ispartofUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISIen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectNon-small-cell lung canceren_US
dc.subjectTargeted therapyen_US
dc.subjectErlotiniben_US
dc.subjectEpidermal growth factor receptoren_US
dc.titleEfficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu